FDA Approves Trastuzumab and Hyaluronidase-oysk for Breast Cancer
On February 28, the Food and Drug Administration approved trastuzumab and hyaluronidase-oysk injection for subcutaneous use (Herceptin Hylecta, Genentech Inc.) for the treatment of HER2-overexpressing breast cancer.
In Person Meeting & NetworkingMay 6, 2026 at 8:00 AM EDT560 King Street, Charleston, SC, USAHyatt Place + Hyatt House Charleston - Historic District, Charleston
In Person Conference & ConventionMay 13, 2026 at 5:30 PM HST6600 Kalanianaʻole Highway suite 110, Honolulu, HI, USARoy's Restaurants – Hawaii Kai, Honolulu
In Person Conference & ConventionMay 20, 2026 at 5:30 PM MDT222 South 22nd Street, Laramie, WY, USAUniversity of Wyoming – Rochelle Gateway Center, Laramie
